Cytokinetics, Incorporated
(NASDAQ : CYTK)

( )
CYTK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.26%87.921.3%$848.13m
BIIBBiogen Inc.
1.64%220.261.3%$580.78m
AMGNAmgen Inc.
-0.06%186.591.2%$533.06m
ONCESpark Therapeutics, Inc.
0.47%113.5311.2%$497.94m
GILDGilead Sciences, Inc.
0.03%63.790.9%$468.70m
REGNRegeneron Pharmaceuticals, Inc.
0.82%395.002.6%$283.62m
ILMNIllumina, Inc.
-1.65%303.713.5%$275.40m
VRTXVertex Pharmaceuticals Incorporated
1.28%183.851.9%$247.78m
SRPTSarepta Therapeutics, Inc.
-2.73%118.9215.4%$216.64m
BPTHBio-Path Holdings, Inc.
-12.42%19.25190.1%$203.41m
ALXNAlexion Pharmaceuticals, Inc.
1.60%132.292.0%$187.73m
EXASExact Sciences Corporation
0.07%89.0625.3%$173.12m
AAgilent Technologies, Inc.
0.66%79.511.6%$122.76m
IONSIonis Pharmaceuticals, Inc.
0.18%79.048.3%$109.28m
INCYIncyte Corporation
0.80%86.022.5%$93.70m

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.